IGC Pharma has expanded its CALMA Phase II clinical trial by adding Integrative Clinical Trials, based in Brooklyn, New York, US, as a new site evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.
Integrative Clinical Trials conducts studies across a broad range of central nervous system (CNS) disorders, including mild cognitive impairment and Alzheimer’s.
The site is led by principal investigator Dr Inna Yuryev-Golger, who has more than ten years of experience in clinical research, and Bella Yevseva, who serves as clinical trial coordinator.
Download sample pages of selected reports
Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.
The centre enhances IGC Pharma’s access to a diverse patient population in a major metropolitan area. The company stated that bringing in sites with CNS experience is central to supporting enrolment and patient engagement for the ongoing study.
IGC-AD1 is an investigational cannabinoid-based therapy being studied in a double-blind, placebo-controlled, randomised Phase II clinical trial for patients experiencing agitation related to Alzheimer’s.
The ongoing expansion of the CALMA trial demonstrates IGC Pharma’s efforts to facilitate patient enrolment and ensure comprehensive clinical monitoring during the study.
IGC develops therapies for Alzheimer’s and metabolic disorders using AI. Its pipeline includes TGR-63 (targeting amyloid plaques), IGC-AD1, and additional early-stage programmes focused on tau proteins, metabolic dysfunctions, and neurodegeneration.
IGC CEO Ram Mukunda said: “Adding Integrative Clinical Trials further strengthens our CALMA clinical network with a site that has deep expertise across CNS disorders.
“Their experience in neuropsychiatric and neurodegenerative research supports our commitment to high-quality data generation and efficient trial execution as we advance IGC-AD1.”
In 2024, IGC Pharma reported the enrolment of two subjects at Neurostudies, a clinical research site in Port Charlotte, Florida, US, for its Phase II trial of IGC-AD1 to treat agitation in Alzheimer’s.
Unlock up to 35% savings on GlobalData reports
Use the code at checkout in the report store
-
20% OFF
Buy 2 reports
Use code:
Bundle20
-
25% OFF
Buy 3 reports
Use code:
Bundle25
-
30% OFF
Buy 4 reports
Use code:
Bundle30
-
35% OFF
Buy 5+ reports
Use code:
Bundle35
Valid on all reports priced $995 and above. Cannot be combined with other offers.
Still deciding what will work best for your business?
Ask our experts for help.
Enquire before buying
